Dencichin (Dencichine)
(Synonyms: 三七素; Dencichin; ODAP) 目录号 : GC31230Dencichin是一种最初从三七中提取的非蛋白质氨基酸,可以抑制HIF-脯氨酰羟化酶2(PHD-2)的活性。
Cas No.:5302-45-4
Sample solution is provided at 25 µL, 10mM.
Dencichin is a non-protein amino acid originally extracted from Panax notoginseng, and can inhibit HIF-prolyl hydroxylase-2 (PHD-2) activity.
Dencichin (β-ODAP, 10 μM, 50 μM, 100 μM and 200 μM) increases HRE expression by 1.3±0.09, 2.5±0.07, 4.2±0.15 and 1.3±0.07 fold respectively compared to control. Dencichin has intermolecular interactions with PHD-2[1]. Dencichin (10 μM, 100 μM, 1 mM) significantly inhibits cell proliferation and extracellular matrix (ECM) proteins accumulation of HBZY-1 cells, and reduces the secretion of collagen I (Col I), collagen IV (Col IV), and fibronectin (FN)[2].
Dencichin improves metabolism disorder in diabetic nephropathy (DN) secondary to type II diabetes mellitus (DM) model. Dencichin (80, 160 mg/kg/day, p.o.) significantly prevents the up-regulation of TCH, TG, LDL, and HbAlc and the down-regulation of HDL in DN rats induced by STZ injection. Dencichin also attenuates renal injury induced in the DN secondary to type II DM model. Dencichin alleviates pancreas damage in the STZ-induced DN model. Dencichin regulates protein expression in the TGF-β/Smad signalling pathway in STZ-induced DN models[2].
[1]. Eslavath RK, et al. β-N-oxalyl-L-α, β- diaminopropionic acid induces HRE expression by inhibiting HIF-prolyl hydroxylase-2 in normoxic conditions. Eur J Pharmacol. 2016 Nov 15;791:405-411. [2]. Jie L, et al. Dencichine ameliorates kidney injury in induced type II diabetic nephropathy via the TGF-β/Smad signalling pathway. Eur J Pharmacol. 2017 Oct 5;812:196-205.
Cell experiment: | Cells are cultured in 6-well plates with glucose (LG) or high glucose control (HG) and then treated with valsartan (1.0 × 10-3 M) or Dencichin (1.0 × 10-5 M, 1.0 × 10-4 M and 1.0 × 10-3 M) for 24 h before analysing the activation of FN, Col I, and Col IV expression by ELISA and analysing MMP-9 and TIMP-1 expression by immunofluorescence. Each experiment is repeated at least three times throughout the study[2]. |
Animal experiment: | Male SD rats weighted approximately 200 ± 20 g (eight weeks old) are kept at 23 ± 2°C. The rats are randomLy allotted into two groups: normal group (n = 16) and diabetic nephropathy (DN) group (n = 60). The normal rats fed with normal diet and vehicle fall into the normal control group (NC, n = 8) and the normal rats fed with normal diet and Dencichin fall into the Dencichin control group (De C, n = 8). The rats in the diabetic group are fed the high-sugar-high-fat diet (composition: Common breeding material 54.6%, lard oil 16.9%, sucrose 14%, casein 10.2%, gunk 2.1%, maltodextrin 2.2%). Five weeks later, DN is induced by administering of 40 mg/kg STZ though intraperitoneal injection, and the normal rats are treated with vehiclecitrate buffer (0.1 M, pH 4.2). Next, the DN rats (n = 32) are assigned into four groups and oral administered with metformin hydrochloride (a positive control) at 80 mg/kg/day, (DN+Met, n = 8), which is dissolve into distilled water to make a 2 mg/mL solution before use; vehicle control for the DN control group (DN, n = 8), or Dencichin. The Dencichin group is divided into a high Dencichin group (160 mg/kg/day; DN+De H, n = 8) and a low Dencichin group (80 mg/kg/day; DN+De L, n = 8), which are dissolved into distilled water to make a 5 mg/mL and 2.5 mg/mL solution before use and oral administered at the dosage once per day. Blood glucose is measured each month. 8 w after administering with Dencichin, the rats are killed[2]. |
References: [1]. Eslavath RK, et al. β-N-oxalyl-L-α, β- diaminopropionic acid induces HRE expression by inhibiting HIF-prolyl hydroxylase-2 in normoxic conditions. Eur J Pharmacol. 2016 Nov 15;791:405-411. |
Cas No. | 5302-45-4 | SDF | |
别名 | 三七素; Dencichin; ODAP | ||
Canonical SMILES | N[C@@H](CNC(C(O)=O)=O)C(O)=O | ||
分子式 | C5H8N2O5 | 分子量 | 176.13 |
溶解度 | Water: 5 mg/mL (28.39 mM); DMSO: 5 mg/mL (28.39 mM) | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 5.6776 mL | 28.3881 mL | 56.7762 mL |
5 mM | 1.1355 mL | 5.6776 mL | 11.3552 mL |
10 mM | 0.5678 mL | 2.8388 mL | 5.6776 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet